Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials

被引：0
|
作者：
Peeters, M.
Van Cutsem, E.
Berlin, J.
Hecht, J. R.
Ruiz, R.
Navale, L.
Amado, R.
Meropol, N. J.
机构：
[1] Ghent Univ Hosp, Ghent, Belgium
[2] Univ Hosp Gasthuisberg, Leuven, Belgium
[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[4] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4138
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer
    Jean, Gary W.
    Shah, Sachin R.
    PHARMACOTHERAPY, 2008, 28 (06): : 742 - 754
  • [32] Cetuximab: An epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer
    Wong, SF
    CLINICAL THERAPEUTICS, 2005, 27 (06) : 684 - 694
  • [33] First line therapy of Panitumumab, a fully human antibody, in combination with FOLFIRI for the treatment (txt) of metastatic colorectal cancer (mCRC)
    Berlin, J.
    Posey, J.
    Tchekmedyian, S.
    Hu, E.
    Chan, D.
    Malik, I.
    Yang, L.
    MacDonald, M.
    Jerian, S.
    Hecht, R.
    EJC SUPPLEMENTS, 2005, 3 (02): : 185 - 185
  • [34] Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis by tumor epidermal growth factor receptor (EGFR) staining
    Peeters, M.
    Cervantes-Ruiperez, A.
    Strickland, A.
    Ciuleanu, T.
    Mainwaring, P. N.
    Tzekova, V. I.
    Santoro, A.
    Johnson, C. W.
    Zhang, A.
    Gansert, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Phase 1 clinical trial of ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) for patients with advanced cancer
    Figlin, R
    Belldegrun, A
    Crawford, J
    Lohner, M
    Roskos, L
    Yang, XD
    Foon, KA
    Schwab, G
    Weiner, L
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 87 - 87
  • [36] EFFECT OF POST-PROTOCOL ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MONOCLONAL ANTIBODY (MAB) THERAPY ON SURVIVAL OUTCOMES IN PATIENTS WITH WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (MCRC) TREATED WITH PANITUMUMAB (PMAB) PLUS CHEMOTHERAPY
    Douillard, J-Y.
    Peeters, M.
    Rong, A.
    Siena, S.
    Braun, S.
    Sidhu, R.
    Price, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 194 - 195
  • [37] Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
    Strumberg, D.
    Schultheis, B.
    Scheulen, M. E.
    Hilger, R. A.
    Krauss, J.
    Marschner, N.
    Lordick, F.
    Bach, F.
    Reuter, D.
    Edler, L.
    Mross, K.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2010, 48 (07) : 473 - 475
  • [38] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXPRESSION ON CIRCULATING ENDOTHELIAL CELLS FROM EGFR-POSITIVE COLORECTAL CANCER (mCRC) PATIENTS
    Danova, M.
    Manzoni, M.
    Chatzileontiadou, S.
    Delfanti, S.
    Valentino, F.
    Mariucci, S.
    Rovati, B.
    Mazzini, G.
    ANNALS OF ONCOLOGY, 2009, 20
  • [39] Expression of the epidermal growth factor receptor (EGFR or HER1) and human epidermal growth factor receptor 2 (HER2) in a large scale metastatic colorectal cancer (mCRC) trial.
    Adenis, A
    Aguilar, EA
    Robin, YM
    Miquel, R
    Penault-Llorca, F
    Castañón, C
    Queralt, B
    Eggleton, SP
    van den Berg, N
    Wilke, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 278S - 278S
  • [40] Clinical Use of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Metastatic Colorectal Cancer
    Patel, Dina K.
    PHARMACOTHERAPY, 2008, 28 (11): : 31S - 41S
12345